ABUS vs MSFT: Which Stock is Better?
Side-by-side comparison of Arbutus Biopharma Corp and Microsoft Corp in 2026
ABUS
Arbutus Biopharma Corp
$4.21
MSFT
Microsoft Corp
$454.79
Key Metrics Comparison
| Metric | ABUS | MSFT | Winner |
|---|---|---|---|
| Market Cap | $780.84M | $3.38T | MSFT |
| P/E Ratio | N/A | 36.30 | MSFT |
| EPS (TTM) | $N/A | $13.70 | MSFT |
| Revenue Growth | -0.6% | 14.9% | MSFT |
| Gross Margin | -98.9% | 68.8% | MSFT |
Analyze ABUS
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ABUS or MSFT a better investment?
Comparing ABUS and MSFT: Arbutus Biopharma Corp has a market cap of $780.84M while Microsoft Corp has $3.38T. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ABUS and MSFT?
ABUS (Arbutus Biopharma Corp) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ABUS or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ABUS or MSFT?
MSFT has higher revenue growth at 14.9% vs -0.6% for ABUS.
Which company is more profitable: ABUS or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.8% compared to -98.9% for ABUS.
Which is the larger company: ABUS or MSFT?
Microsoft Corp (MSFT) is larger with a market cap of $3.38T compared to $780.84M for ABUS.
Should I buy ABUS or MSFT in 2026?
Both ABUS and MSFT have investment merit. ABUS trades at $4.21 while MSFT trades at $454.79. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ABUS and MSFT stock?
Key differences: Market Cap ($780.84M vs $3.38T), P/E Ratio (N/A vs 36.3x), Revenue Growth (-0.6% vs 14.9%), Gross Margin (-98.9% vs 68.8%).